Nineteen patients with Tourette syndrome (TS) were treated with risperidone, at a mean daily dose of 1.5 mg. Of those, 41% responded positively, 35% felt that it had made no difference, while it made 24% worse. Although 53% of the patients experienced side-effects, none had extrapyramidal side-effects. At follow-up, 8 to 11 months later, only two of 19 (11 %) patients were still taking risperidone. We suggest that risperidone does have a role in a minority of TS sufferers but it is not suggested as the first line treatment. More placebo-controlled studies using risperidone are clearly indicated.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd edn, revised) (DSM III R). American Psychiatric Association , Washington, DC
2.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (4th edn). American Psychiatric Association, Washington, DC
3.
Baker G.B., Chokka P.R., Bornstein R.A. (1995) Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update. Psychopharmacology9: 273-280
4.
Benkelfat C., Murphy D.L., Zohar J., Hill J.D., Grover G., Insel T. (1989) Clomipramine in obsessive-compulsive disorder. Arch Gen Psychiatr46: 23-28
5.
Borison R.L., Pathiraja A.P., Diamond B.I., Meibach R.C. (1992) Risperidone: clinical safety and eflicacy in schizophrenia . Psychopharmacol Bull28: 213-218
6.
Bruggeman R., Linden van der C, Woerkom van C A M (1994) Risperidone in the treatment of Gilles de la Tourette's syndrome — an open dose finding study. Neuropsychopharmacology10: (3S) (Suppl. part 2), 42S, O-115-163
7.
Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol13 : 25-40
8.
Cosgrove F. (1994) Recent advances in paediatric psychopharmacology . Hum Psychopharmacol9: 381-382
9.
Desai A.B., Doongaji D.R., Satoskar R.S. (1983) Metoclopramide in Gilles de la Tourette's syndrome . J Postgrad Med29:181-183
10.
Dursun S.M., Handley S.L. (1991) Tic-like behaviours induced by TRH-amide: differential effects of ritanserin and haloperidol. Br J Pharmacol102: 229P
11.
Dursun S.M., Handley S.L. (1992) Behavioural profile of -MSH: differential effects of ritanserin, haloperidol and clonidine. J Psychopharmacol (Suppl. 37P)
12.
Dursun S.M., Handley S.L. (1994) Complex of rapid movements and vocalization induced by RX336-M in mice: possible relevance to Tourette's syndrome. J Psychopharmacol8: 27-31
13.
Dursun S.M., Reveley M.A. (1994) Obsessive-compulsive symptoms and clozapine. Br J Psychiatr165: 267-268
14.
Dursun S.M., Handley S.L., Reveley M.A. (1994) Behavoural profile of ACTH(1-39): differential effects of haloperidol and ritanserin. Br J Pharmacol112: 622P
15.
Dursun S.M., Reveley M.A., Bird R., Stirton F. (1994) Longlasting improvement of Tourette's syndrome with transdermal nicotine. Lancet344:1577
16.
Eapen V., Trimble M.R., Robertson M.M. (1996) The use of fluoxetine in Gilles de la Tourette Syndrome and obsessive compulsive behaviours: preliminary clinical experience . Prog Neuro-Psychopharmacol Biol Psychiatr20, 737-743
17.
Eggers C.H., Rothenberger A., Berghaus U. (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Europ Arch Psychiatr Neurolog Sci237: 223-229
18.
George M.S., Trimble M.R., Robertson M.M. (1993) Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette Syndrome. Hum Psychopharmacol8: 327-334
19.
Hemming M.,Yellowlees P.M. (1993) Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol7:389-391
20.
Jacobsen F.M. (1995) Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatr56: 423-429
21.
Leckman J.F., Detlor J., Harcherick D.F., Ort S., Shaywitz B.A., Cohen D.J. (1985) Short and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective. Neurology35: 343-351
22.
Leckman J.F., Towbin K.E., Ort S.I., Cohen D.J. (1988) Clinical assessment of tic disorder severity. In Cohen D J, Bruun R D, Leckman J F (eds), Tourette's syndrome and tic disorders. Wiley, New York, pp. 55-78
23.
Leckman J.F., Riddle M.A., Hardin M.T., Ort S.I., Swartz K.L., Stevenson J., Cohen D.J. (1989) The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adol Psychiatr28: 566-573
24.
Leysen J.E., Janssen P M F, Gommeren W., Wynants J., Pauwels P.J., Janssen P A J (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Molec Pharmacol41: 494-508
25.
Lombroso P.J., Scahill L., King R.A., Lynch K.A., Chappell P.B., Peterson B.S., McDougle C.J., Leckman J.F. (1995) Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adol Psychiatr34: 1147-1152
26.
Reveley M.A., Bird R., Stirton R.F., Dursun S.M. (1994) Microstructural analysis of the symptoms of Tourette's syndrome and the effects of a trial use of transdermal nicotine path. Psychopharmacology (Suppl. A30) 117
27.
Robertson M.M. (1989) The Gilles de la Tourette syndrome: the current status. Br J Psychiatr154:147-169
28.
Robertson M.M. (1994) Annotation: Gilles de la Tourette syndrome — an update. J Child Psychol Psychiatr35: 597-611
29.
Robertson M.M. (1995) The relationship between Gilles de la Tourette syndrome and obsessive compulsive disorder. J Serotonin Res (Suppl. 1): 49-62
30.
Robertson M.M., Gourdie A. (1990) Familial Tourette's syndrome in a large British pedigree: associated psychopathology, severity of Tourette's and potential for linkage analysis. Br J Psychiatr156: 515-521
31.
Robertson M.M., Eapen V. (1992) The pharmacologic controversy of CNS stimulants in Gilles de la Tourette syndrome. Clin Neuropharmacol15: 408-425
32.
Robertson M.M., Eapen V. (1996) The National Hospital interview schedule for the assessment of Gilles de la Tourette syndrome. Int J Meth Psychiatr Res (in press)
33.
Robertson M.M., Trimble M.R., Lees A.J. (1988) The psychopathology of the Gilles de la Tourette syndrome: a phenomenological analysis. Br J Psychiatr152: 383-390
34.
Robertson M.M., Schnieden V., Lees A.J. (1990) Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol13: 229-235
35.
Robertson M.M., Channon S., Baker J., Flynn D. (1993) The psychopathology of Gilles de la Tourette syndrome: a controlled study. Br J Psychiatr162:114-117
36.
Shapiro E., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J., Phillips R.A. (1989) Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de laTourette's syndrome. Arch Gen Psychiatr46: 722-730
37.
Silver A.A., Sanberg P.R. (1993) Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet342: 182
38.
Stamenkovic M., Aschauer H., Kasper S. (1994) Risperidone for Zburette's syndrome. Lancet344:1577-1578
39.
van der Linden C., Bruggeman R., van Woerkom Cam (1994) Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disorders9: 687-688
40.
World Health Organisation (1992) International classification of diseases and health related problems (10th revision). World Health Organisation, Geneva
